SME Times is powered by   
Search News
Just in:   • Adani Group to invest Rs 57,575 crore in Odisha  • 'Dollar Distancing' finally happening? Time for India to pitch Rupee as credible alternative: SBI Ecowrap  • 49% Indian startups now from tier 2, 3 cities: Jitendra Singh  • 'India ranks 3rd in global startup ecosystem & number of unicorns'  • LinkedIn lays off entire global events marketing team: Report 
Last updated: 27 Mar, 2021  

Tablet.9.Thmb.jpg Pharma opportunities between India, Australia identified

   Top Stories
» 28 Indian startups raised over $800 mn in funding this week
» GST Council waives interest, penalty on notices to taxpayers under Section 73
» India's innovation ecosystem poised for exponential growth: Industry
» India's innovation ecosystem poised for exponential growth: Industry
» Overseas Indians faith grows in Indian economy with $1 billion deposits in April
SME Times News Bureau | 26 Mar, 2021

Industry body FICCI and Australia-India business body AIBC Thursday jointly organised a roundtable on 'Opportunities and Challenges in Pharmaceutical Partnerships between India and Australia' to promote Make in India initiative.

During the India-Australia Summit in June 2020, bilateral cooperation between India and Australia has been elevated from Strategic Partnership to Comprehensive Strategic Partnership.

Taking the momentum forward, both FICCI and Australia India Business Council (AIBC) have initiated 'Comprehensive Business Partnership' - a joint effort under Make in India initiative.

The purpose of organizing the roundtable was to facilitate an active and mutually beneficial interaction between Indian and Australian companies to constructively deliberate and share best practices and successfully identify sector-specific challenges and opportunities that lies ahead.

Pharmaceutical sector is of utmost importance in today's scenario. India is the 3rd largest pharmaceuticals industry in the world by volume.

The Indian pharmaceutical industry has contributed significantly to global healthcare market by ensuring high quality, affordable and accessible medicines around the world.

On the other hand, the life sciences sector is a sector of strategic priority for Australia as well.

Its competitive and path breaking research can offer huge opportunities for India to build meaningful collaborations.

The discussions of the Roundtable meeting centered around the key areas of collaboration such as R&D and innovation, clinical trials, affordable generics and biosimilars, harmonization of regulatory practices and the increasing emphasis on alternative medicines in the prevailing pandemic situation.

Australian participants highlighted that Ayurvedic, herbals and botanicals are the new emerging areas for collaboration for India-Australia as healthcare is addressed in more holistic manner by consumers with changing patterns of lifestyle disorders.

Australian side also stressed on the collaboration between two countries in the areas of standards especially medical labelling, generics, community pharmacies.

The Indian industry raised the issue of recognition of Indian pharmaceuticals by Therapeutic Goods Administration of Australia in view of the approval of pharma manufacturing plants by USFDA.

The meeting concluded with both sides agreeing to lay more emphasis on the clinical trials and the conducive regulatory environment for harmonization provided by India and Australia.

Print the Page
Add to Favorite
Share this on :

Please comment on this story:
Subject :
(Maximum 1500 characters)  Characters left 1500
Your name:

  Customs Exchange Rates
Currency Import Export
US Dollar
UK Pound
Japanese Yen 58.85 56.85
As on 13 Aug, 2022
  Daily Poll
Will the Budget 2024 be MSME friendly
 Can't say
  Commented Stories
» GIC Re's revenue from obligatory cession threatened(1)
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter